Compare AGNC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | LEGN |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 5.9B |
| IPO Year | 2008 | 2020 |
| Metric | AGNC | LEGN |
|---|---|---|
| Price | $10.44 | $21.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $10.16 | ★ $69.67 |
| AVG Volume (30 Days) | ★ 19.9M | 2.7M |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $956,000,000.00 | $909,045,000.00 |
| Revenue This Year | $8.02 | $68.83 |
| Revenue Next Year | $65.46 | $51.27 |
| P/E Ratio | $14.68 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $7.85 | $21.51 |
| 52 Week High | $10.67 | $45.30 |
| Indicator | AGNC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 20.03 |
| Support Level | $10.28 | $26.43 |
| Resistance Level | $10.67 | $28.97 |
| Average True Range (ATR) | 0.14 | 1.25 |
| MACD | -0.02 | -0.41 |
| Stochastic Oscillator | 40.81 | 0.73 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.